

(12) UK Patent Application (19) GB (11) 2 097 783 A

(21) Application No 8112600

(22) Date of filing

23 Apr 1981

(43) Application published

10 Nov 1982

(51) INT CL³ C07D 233/94
A61K 31/415

(52) Domestic classification
C2C1410 200 215 221
226 22Y 250 252 25Y
30Y 332 366 368 491
621 628 658 65X 671
681 802 80Y AA ML
A5B170 360 36Y 38Y
390 39X 401 40Y 423
426 42Y 461 466 46Y
513 51Y 542 54Y 565
56Y 586 58Y 664 66Y J

(56) Documents cited

None

(58) Field of search

C2C

(71) Applicant

Dermal Laboratories
Limited
Tatmore Place
Gosmore
Nr Hitchin
Hertfordshire

(72) Inventors

Martin Whitefield
Marcel Weinstock

(74) Agents

J A Kemp and Co
14 South Square
Gray's Inn
London WC1R 5EU

(54) Imidazoles

(57) Metronidazole retinoate and
mizonidazole retinoate are useful in
the treatment of acne by topical
application. Pharmaceutical compo-
sitions comprising retinoic acid or a
lower alkyl ester thereof and an
ester of metronidazole or mizonida-
zole with an acid of formula
RCOOH, in which R is an aliphatic
residue such that RCOOH is an ali-
phatic acid of 3 to 10 carbon
atoms, are useful for the same pur-
pose.

GB 2 097 783 A

SPECIFICATION

Compounds and compositions useful in the treatment of acne

5 This invention relates to the compounds and compositions useful in the treatment of acne. 5


Acne is a disfiguring and frequently embarrassing condition which affects certain areas of the skin which are rich in sebaceous glands, especially the face, neck and back. It occurs most frequently in adolescents. While the precise cause of acne is not fully understood, it results from an abnormality of the sebaceous glands and blockage of the pilosebaceous ducts due to a 10 combination of factors. These include hyperkeratosis of the follicular duct, an increase in the amount and change in the composition of the sebum, and the colonisation of the sebaceous follicles by bacteria, especially *Propionobacterium* or *Corynebacterium acnes*. These effects produce the characteristic acne lesions, chiefly comedones, papules and pustules together with generalised inflammation. A variety of therapeutic treatments for acne are currently in use, and 15 these are based in the main on keratolytics which reduce the hyperkeratinisation or antibiotics which minimise the effects of the bacterial infection. 15

One method of treatment which has attracted considerable interest in recent years is the use of retinoic acid (Vitamin A acid) applied topically to the lesions. Retinoic acid has a very marked keratolytic effect on the epidermis and a proportion of acne patients benefit from its use. It 20 causes peeling of the skin and unblocks the pilosebaceous ducts. However, since retinoic acid is highly irritant, some patients do not benefit from its use, and may indeed suffer undesirable side effects. 20

It has also been proposed to treat acne by oral antibiotic therapy using, in particular, tetracyclines. It is believed that where this treatment is successful, it is the action of the antibiotic on 25 harmful bacterial metabolites which is responsible for the beneficial effect. Another method of treatment of some interest involves the topical application of ethyl lactate to the affected area. The bacterial esterases in the sebaceous ducts hydrolyse the ethyl lactate with liberation of lactic acid which suppresses the growth of the bacteria. Thus the bacteria are themselves responsible for producing the hydrolysis of the ethyl lactate which prevents their further growth. 25

30 The present invention provides novel compounds and compositions for use in the treatment of acne. The bacteria present in the sebaceous glands in acne are predominantly anaerobic which explains why tetracyclines do not actually destroy them directly. Two agents which are known to be highly effective against anaerobic bacteria are the nitromidazoles, metronidazole and mizonidazole. However, these compounds have poor solubility in lipids and cannot therefore be 35 applied directly to skin with any expectation that they will reach the interior of the sebaceous glands populated by the bacteria. The present invention provides nitroimidazole derivatives and compositions which are effective in the treatment of acne. 35


The invention provides, as new compounds useful in the treatment of acne, the nitroimidazole derivatives of the formula: 40



where the nitro group is in the 4- or 5-position of the imidazole ring. These compounds are the retinoates of metronidazole (the 5-nitro compound) and mizonidazole (the 4-nitro compound). 50

50 These compounds are lipid-soluble and when applied topically to an area of skin affected by acne, penetrate well into the epidermis. When the compounds reach the sebaceous glands, they are hydrolysed by the bacterial esterases present, thus liberating both the nitroimidazole itself which is then effective against those anaerobic bacteria, and retinoic acid, which exerts its beneficial keratolytic effect on the hyperkeratotic lining of the pilosebaceous duct and the keratin 55 anchoring the comedones. Consequently, by esterifying the nitroimidazole derivative with retinoic acid, the beneficial effects of both are secured in the place, namely the interior of the pilosebaceous duct, where they are required. 55

60 Alternatively, according to a further feature of the invention, a similar effect can be secured by applying to the skin affected by acne a pharmaceutical composition comprising retinoic acid or a lower alkyl ester thereof and a nitroimidazole ester of the formula: 60



5

in which R is an aliphatic residue such that RCOOH is an aliphatic carboxylic acid of 3 to 10 carbon atoms. However R should be substantially free of groups which would make the ester insoluble in lipids. Thus groups normally associated with water-solubility, e.g. hydroxyl and carboxyl, are not desirable. Conveniently R is a residue of an alkanecarboxylic acid of 3 to 10 carbon atoms, e.g. propionic acid, butyric acid or valeric acid.

10

When such a composition is applied to skin affected by acne, the retinoic acid penetrates to the pilosebaceous ducts with the nitroimidazole ester, and the latter is hydrolysed *in situ* by the esterases present. The desirable effect of retinoic acid and the nitro-imidazole itself are thus secured at the locus of the affection. Of course, if a retinoic acid ester is used, such an ester is also hydrolysed in the vicinity of the sebaceous gland with liberation of free retinoic acid.

15

The aforesaid retinoate of nitroimidazole may be made by reaction of metronidazole or mizonidazole with retinoic acid chloride, prepared *in situ*, e.g. by the action of thionyl chloride or retinoic acid in an inert solvent in the presence of a base, in an inert solvent in the presence of a base. For example, the nitroimidazole may be reacted with the acid chloride in solution in tetrahydrofuran, in the presence of an organic base soluble in the reaction mixture such as pyridine. This process is illustrated by the following Example.

20

25 Example

25

Metronidazole Retinoate (2-Methyl-5-Nitroimidazole-1-Ethanol Retinoate)

To a solution of retinoic (5 g) and pyridine (1.6 g), in dry tetrahydrofuran (50 ml), thionyl chloride (2.1 g) in tetrahydrofuran (5 ml) was added at 0°C. over 15 minutes, under nitrogen, 30 with stirring. The mixture was stirred at room temperature for 1 hour and then filtered. The filtrate was added over 10 minutes at 35°C. to a solution of 2-methyl-5-nitroimidazole-1-ethanol (3 g), 4-dimethylaminopyridine (0.1 g), and pyridine (1.5 g) in dry tetrahydrofuran (90 ml). The mixture was stirred under reflux for 8 hours. The tetrahydrofuran (ca 60 ml) was then distilled off and the residue stirred under reflux for a further 8 hours. The reaction

30

35 mixture was filtered and the solvent evaporated *in vacuo*. The residue was dissolved in chloroform (100 ml) and the solution washed with 2N sulphuric acid (2x50 ml), water (50 ml), 10% aqueous sodium bicarbonate (50 ml), and water (50 ml). The chloroform solution was then dried over sodium sulphate and evaporated *in vacuo*. The residue was purified by multi-funnel liquid-liquid extraction between light petroleum spirit (b.p. 40-60°C.) and 95% aqueous

35

40 methanol to yield 2-methyl-5-nitroimidazole-1-ethanol retinoate as an orange-yellow gum (6 g) which solidifies on cooling.

40

The product was purified by TLC (silica gel plates; ethyl acetate/light petroleum 1:1) in ca 100% yield.

45 The N.M.R. spectrum showed peaks at 0.9 ppm (gem dimethyl protons in acid component), 2.2 ppm ($\text{CH}_3-\text{C}=\text{C}-$ protons in acid component), 6.1 ppm (vinylic protons in acid component), and 8 ppm (vinylic proton in imidazole ring of alcohol component). The N.M.R. data confirm that the ester contains the essential characteristics of both the metronidazole and retinoic acid moieties.

45

50 Esters of metronidazole and mizonidazole with aliphatic carbocyclic acids of the formula RCOOH (in which R is as hereinbefore defined) may be prepared by well established procedures from metronidazole or mizonidazole and either a halide of the acid or the free acid itself.

50

The nitroimidazole retinoates of formula I may be applied to skin affected by acne either in the pure state, or in an appropriate pharmaceutical composition for topical application. In addition to the active ingredient, such compositions may contain appropriate inert diluents known for use in 55 pharmaceutical compositions for topical application to the skin. The composition must, of course, contain sufficient of the retinoate to produce the desired effect. A concentration of from 0.1 to 5.0% by weight of the composition is generally appropriate. In order to assure maximum stability of the composition, it may be formulated in a substantially anhydrous ointment base containing an appropriate oil-soluble antioxidant such as 2, 6-diteriary butyl *para*-cresol.

55

60 Alternatively, it may be formulated as a cream, when the retinoate would be incorporated into the oleaginous phase while a water-soluble antioxidant such as ascorbic acid would be dissolved in the aqueous phase. In lower concentrations it may also be used as an alcoholic solution or gel. The aforesaid pharmaceutical compositions comprising retinoic acid or a lower alkyl ester thereof and a nitroimidazole ester of formula II may be similarly made up using

60

65 conventional diluents compatible with the active ingredients also including alcholic solutions or

65

gels for lower concentrations. It is normally appropriate for such compositions to contain 0.01 to 5% by weight of the retinoic acid or ester thereof and 0.1 to 5.0% by weight of the nitroimidazole ester.


The following Examples of suitable formulations illustrate the invention.

5	Ingredients	Parts by weight	5
10	<i>Example I</i> Metronidazole Retinoate 0.5 Antioxidant 0.2 White soft paraffin to 100.0		10
15	<i>Example II</i> Metronidazole Retinoate 0.5 White soft paraffin 35.0 Cetomacrogol emulsifying wax 10.0 Ascorbic acid 0.2 Chlorocresol 0.1 Purified water 100.0		15
20	<i>Example III</i> Metronidazole Propionate 1.0 Retinoic acid 0.025 Propylene glycol 15.0 Alcohol to 100.0		20
25	<i>Example IV</i> Metronidazole Propionate 1.0 Ethyl retinoate 0.5 Propylene glycol 15.0 Alcohol to 100.0		25

30 The above compositions are suitable for application to the skin to treat acne. 30


CLAIMS

1. A nitroimidazole derivative of the formula:



in which the nitro group is attached to the 4- or 5- position of the imidazole ring.

2. Metronidazole retinoate.
3. A pharmaceutical composition for topical application comprising retinoic acid or a lower 45 alkyl ester thereof and a nitroimidazole ester of the formula:



55 wherein R is an aliphatic residue such that RCOOH is an aliphatic carboxylic acid of 3 to 10 carbon atoms.

4. A pharmaceutical composition according to claim 3 comprising retinoic acid and the propionate, butyrate or valerate, of metronidazole.
5. A pharmaceutical composition according to claim 3 or 4, comprising 0.01 to 5.0% by weight of retinoic acid or a lower alkyl ester thereof and 0.1 to 5.0% by weight of a said 60 nitroimidazole ester in association with 90.0 to 99.89% by weight of a compatible pharmaceutical carrier.
6. A pharmaceutical composition as claimed in claim 3 substantially as described in Example I, II, III or IV.
7. Process for the preparation of a nitroimidazole retinoate as claimed in claim 1 which 65 comprises reacting metronidazole or mizonidazole with a retinoic acid halide.

8. Process according to claim 7 in which the retinoic acid halide is produced *in situ* by the reaction of retinoic acid with thionyl chloride in the presence of a base.
9. Process according to claim 7 or 8, in which metronidazole is reacted with retinoic acid chloride in the presence of an inert organic solvent and an organic base.
- 5 10. Nitroimidazole retinoates when prepared by a process claimed in any of claims 7 to 9. 5

Printed for Her Majesty's Stationery Office by Burgess & Son (Abingdon) Ltd.—1982.
Published at The Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.